Global
Renal Denervation Market estimated at $140 Million (2022), is
growing at a healthy CAGR of 40% y 2027. The market growth
is driven by the growing geriatric population, the rising prevalence of
hypertension, and venture capital funding. The U.S. market is likely to offer
high growth opportunities in next 3-5 years.
Resistant hypertension is a blood pressure that remains
elevated above target levels despite use of anti-hypertensive medications.
About 12-15% of the population treated for high blood pressure suffers from
resistant hypertension. Renal denervation is a minimally invasive procedure
used to treat resistant hypertension. As the geriatric population is growing,
the number of people suffering from hypertension and the resistant hypertension
is also growing which is driving the RDN market growth.
Download a free sample report now 👉
https://meditechinsights.com/global-renal-denervation-market/request-sample/
The rising prevalence of hypertension is driving the
Renal Denervation Market Growth
According to WHO, currently more than one billion people
across the globe are suffering from hypertension which is expected to grow to
1.6 billion by 2025. WHO estimated that less than one in five people have their
hypertension under control, either due to non-adherence or resistance to
medications. This is leading to growing prevalence of hypertension/resistant
hypertension, thereby driving the Renal Denervation market growth.
Lack of long-term clinical data and risks associated with
RDN procedure inhibits the Renal Denervation market growth
Though Renal Denervation is perceived as potential treatment
for resistant hypertension, it is a relatively new procedure and less data is
available on its long-term effects. Owing to the limited clinical evidence, the
RDN products are available only for investigational purpose in some of the
major markets. For instance, Medtronic’s Symplicity Spyral RDN System’s use is
limited only to investigational purpose in the U.S., Japan, and Canada.
Further, there are various risks associated with this procedure which limits
its use. Some patients experience bradycardia during the procedure. The RF
ablation may cause changes to the wall of the arteries, which can sometimes
lead to renal artery stenosis. The imaging used during the procedure also has a
number of risks. Other complications include tearing in the renal arteries and
pseudoaneurysm (a bruise caused by a leaking hole in an artery).
North America to offer high growth opportunities in Renal
Denervation Market
From a geographic perspective, Europe is the single largest
renal denervation market. This is mainly attributed to the growing aging
population, rising prevalence of hypertension, and higher penetration due to
commercial availability of RDN products within Europe. The North American
market is at nascent stage as the RDN companies are yet to launch the products
for commercial use in the region. However, the companies in the RDN market are
thriving to introduce their products in the U.S. market and are focusing their
efforts on getting the commercial approvals. For instance, Medtronic is likely
to publish its results of SPYRAL HTN-ON MED clinical trials for its RDN system
in the U.S. in later half of 2022. Further, in March 2022, ReCor Medical
(Otsuka) completed subject enrolment for its RADIANCE-II pivotal trial of its
Paradise Ultrasound Renal Denervation (uRDN) System for generating clinical
trial data to enter the U.S. market.
Some key players operating in the global renal denervation
market include Medtronic, Boston Scientific Corporation, St. Jude Medical
(Abbott), ReCor Medical (Otsuka), Cordis Corporation, and Terumo Corporation,
among others.
Download a sample report for in-depth competitive
insights
https://meditechinsights.com/global-renal-denervation-market/request-sample/
Citing the growth potential of Renal Denervation Market,
venture capital firms are helping start-ups to expedite their clinical trial
efforts
- In
December 2021, SyMap Medical completed financing round of $100 million led
by Primavera Capital and VMS Group, with the participation of existing
investors Simiao Equity Investment and Sequoia Capital China.
- In
April 2021, China-based renal denervation firm Brattea completed $20
million funding round. The round was led by led by healthcare private
equity fund Kuanping Capital.
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights
firm. Our clients include Fortune 500 companies, blue-chip investors &
hyper-growth start-ups. We have completed 100+ projects in Digital Health,
Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the
areas of market assessments, due diligence, competitive intelligence, market
sizing and forecasting, pricing analysis & go-to-market strategy. Our
methodology includes rigorous secondary research combined with deep-dive
interviews with industry-leading CXO, VPs, and key demand/supply side
decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
Comments
Post a Comment